Aqua Pharmaceuticals has added low-potency foam corticosteroid to its dermatology portfolio with the acquisition of US rights and re-launch of Verdeso (desonide) Foam, 0.05% from Stiefel, a GSK company.
Indicated for the topical treatment of mild to moderate atopic dermatitis in patients aged three months and more, Verdeso foam is emollient-based, ethanol-free and unavailable in generic form.
Aqua chief executive officer Craig Ballaron said the company's product portfolio include Monodox capsules, Xolegel gel, Fluoroplex topical cream and Cordran cream and lotion.
"I would also like to acknowledge the important role RoundTable Healthcare Partners played in this acquisition," Ballaron added.
Their transaction expertise and relationship with GSK were key elements in completing this deal."
All manufacturing, distribution and promotion activities related to the product will be carried out by Aqua.
